Clinical Trials
8 trialsNCT00954226 2025-09-05
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00079053 2023-08-04
Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Canadian Cancer Trials Group
Phase 1 Completed
NCT01332279 2023-04-04
Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
Fox Chase Cancer Center
Phase 1 Withdrawn
NCT01316757 2018-02-26
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00397384 2015-09-30
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00101348 2014-06-11
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00055770 2013-11-25
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00030498 2013-01-16
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed